Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. MSTR

Go back to Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
(NASDAQ: WVE) Delayed: 6.22 +0.06 (0.97%)
Previous Close $6.16    52 Week High $38.50 
Open $6.13    52 Week Low $8.95 
Day High $6.30    P/E N/A 
Day Low $6.09    EPS $0.00 
Volume 1,763,173       

(NASDAQ: WVE) Delayed: 6.22 +0.06 (0.97%)
Previous Close $6.16    52 Week High $38.50 
Open $6.13    52 Week Low $8.95 
Day High $6.30    P/E N/A 
Day Low $6.09    EPS $0.00 
Volume 1,763,173